- Solid Biosciences Inc (NASDAQ:SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.
- In addition, the Company plans to narrow Research & Development activities to those related to SGT-001, SGT-003, and next-generation capsids.
- Related: Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial.
- Due to the reorganized pipeline, the Company will slash its headcount by 35% and plan to extend its current funds through mid-2024.
- Solid Biosciences ended the March quarter with a cash balance of $180.1 million.
- COO Joel Schneider will leave the Company at the end of May to become CEO of a private gene therapy biotech.
- Solid has concluded enrollment in IGNITE DMD Phase 1/2 trial for SGT-001 and will continue monitoring dosed patients for five years post-treatment. The Company currently expects to continue dosing with SGT-001 in 2023.
- The Company remains on track for an early 2023 IND submission for SGT-003.
- Price Action: SLDB shares are down 13.8% at $0.67 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks